REV-ERB agonism improves liver pathology in a mouse model of NASH.
REV-ERB agonism improves liver pathology in a mouse model of NASH.
复制标题
DOI:
10.1371/journal.pone.0236000
复制
发表时间:
2020
期刊:
影响因子:
3.7
通讯作者:
Burris TP
中科院分区:
文献类型:
--
作者:
Griffett K;Bedia-Diaz G;Elgendy B;Burris TP
Non-alcoholic fatty liver disease (NAFLD) affects a significant number of people worldwide and currently there are no pharmacological treatments. NAFLD often presents with obesity, insulin resistance, and in some cases cardiovascular diseases. There is a clear need for treatment options to alleviate this disease since it often progresses to much more the much more severe non-alcoholic steatohepatitis (NASH). The REV-ERB nuclear receptor is a transcriptional repressor that regulates physiological processes involved in the development of NAFLD including lipogenesis and inflammation. We hypothesized that pharmacologically activating REV-ERB would suppress the progression of fatty liver in a mouse model of NASH. Using REV-ERB agonist SR9009 in a mouse NASH model, we demonstrate the beneficial effects of REV-ERB activation that led to an overall improvement of hepatic health by suppressing hepatic fibrosis and inflammatory response.
登录
查看更多内容
影响因子:
8.1
作者:
Griffett K;Welch RD;Flaveny CA;Kolar GR;Neuschwander-Tetri BA;Burris TP
通讯作者:
Burris TP
影响因子:
29.4
作者:
Pourcet B;Zecchin M;Ferri L;Beauchamp J;Sitaula S;Billon C;Delhaye S;Vanhoutte J;Mayeuf-Louchart A;Thorel Q;Haas JT;Eeckhoute J;Dombrowicz D;Duhem C;Boulinguiez A;Lancel S;Sebti Y;Burris TP;Staels B;Duez HM
通讯作者:
Duez HM
影响因子:
3.5
作者:
Feng, Gong;Li, Xue-Ping;Mi, Man
通讯作者:
Mi, Man
影响因子:
4
作者:
Griffett, Kristine;Solt, Laura A.;Burris, Thomas P.
通讯作者:
Burris, Thomas P.
影响因子:
3.7
作者:
Stujanna EN;Murakoshi N;Tajiri K;Xu D;Kimura T;Qin R;Feng D;Yonebayashi S;Ogura Y;Yamagami F;Sato A;Nogami A;Aonuma K
通讯作者:
Aonuma K